CURRENT AFFAIRS

Detailed explanation-1: -Experts at the Public Health Agency of Canada originally developed the vaccine, which is now licensed to Merck. NIAID and the Walter Reed Army Institute of Research (WRAIR) evaluated rVSV-ZEBOV in Phase 1 clinical trials which showed rVSV-ZEBOV is safe and able to induce a robust immune response in recipients.

Detailed explanation-2: -The Zabdeno and Mvabea vaccine was studied in a total of 3 367 adults, adolescents and children who participated in 5 clinical studies conducted in Europe, Africa and the United States of America. These studies demonstrated that the vaccine regimen is safe and could induce an immune response against the Ebola virus.

Detailed explanation-3: -Merck anticipates that it will fill approximately 50,000 doses for IAVI from the existing bulk drug substance by the end of 2022. Further use in the response to the outbreak will be subject to authorization by applicable health authorities. Dr.

Detailed explanation-4: -Ebola trial candidate vaccines arrive in Uganda in record 79 days after outbreak declared. The first doses of one of the three candidate vaccines against Sudan ebolavirus arrived in Uganda yesterday.